Embecta Corp.

EMBC Healthcare Medical Instruments & Supplies

Embecta Corp.’s revenue for fiscal 2025 (year ended September 2025) was $1.1 billion, down 3.80% from fiscal 2024. In the quarter to June 2026, revenue fell 8.05%, EPS fell 53.9%, free cash flow fell 49.6% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.27 0.18 −2.79%
Market cap
$365.5M
P/E
4.2×
Fwd P/E
3.8×
Dividend yield
5.10%
F-score
7/9
Altman Z
1.84
Beneish M
−3.11
Dividend safety
56/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

8.66 4.99 4.63 2.19
P/S ratio
0.76 0.65 0.50 0.19
P/FCF ratio
4.51 3.24 2.44 1.09
P/Operating CF
9.79 40.61 16.86 4.56
P/B ratio
0.00 0.00 0.00 0.00
EV/Sales
1.87 1.75 1.62 1.43
EV/EBITDA
6.69 5.27 5.09 5.06
EV/FCF
11.08 8.73 7.84 8.33
Current Ratio
2.41 2.64 2.46 1.68
Net Debt/EBITDA
16.02 12.09 23.36 19.39
Debt/Equity
(2.19) (2.27) (2.16) (2.42)
Earnings Yield
11.55% 20.03% 21.61% 45.71%
Free Cash Flow Yield
22.17% 30.91% 40.98% 91.64%
Free Cash Flow per Share
1.32 0.45 0.52 0.70
Book value per Share
(11.16) (10.43) (10.56) (10.48)
Free Cash Flow
76.70 26.70 30.60 40.70
EV/EBIT
8.35 6.35 6.27 6.51
Other line items

Show all line items

Columns are period end dates